Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
123-I-MIP-1072 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Previous ProstaScint® | EXPERIMENTAL | Subjects with a previous 111-In capromab pendetide image of sufficient quality obtained within 60 days of study enrollment will receive 123-I-MIP-1072 alone. |
| No Previous ProstaScint® | EXPERIMENTAL | Subjects without a previous 111-In capromab pendetide image of sufficient quality obtained within 60 days of study enrollment will receive 123-I-MIP-1072 and 111-In capromab pendetide imaging. |
| 1 | EXPERIMENTAL | 123-I-MIP-1072 administration followed by 123-I-MIP-1095 administration two weeks later. |
| 2 | EXPERIMENTAL | 123-I-MIP-1095 administration followed by 123-I-MIP-1072 administration two weeks later. |
| Name | Type | Description |
|---|---|---|
| 123-I-MIP-1072 | DRUG | Single 10 mCi intravenous injection |
| 111-In capromab pendetide | DRUG | Single 5 mCi intravenous injection |
| 123-I-MIP-1095 | DRUG | 10 mCi intravenous injection given one time during the study |
Subjects must meet all of the following criteria to be enrolled in this study. 1. Male aged 18 years or older 2. Signed written informed consent and willingness to comply with protocol requirements 3. Histologic diagnosis of prostate cancer by validated history and/or biopsy of the prostate or of a...
Top 20 of 53 competitors
123-I-MIP-1072 is an investigational small molecule imaging agent being studied for use in prostate cancer. It is designed to help visualize prostate cancer, including metastatic disease, through imaging. The drug is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
123-I-MIP-1072 is being developed by Insight Molecular Diagnostics Inc., a company listed under the ticker IMDX. The company is conducting clinical trials to evaluate the safety and imaging capabilities of this investigational agent in patients with prostate cancer.
123-I-MIP-1072 is in Phase 1 clinical development. Two Phase 1 trials have been completed, with a total of 36 participants enrolled. The drug remains investigational and has not received FDA approval for any indication.
123-I-MIP-1072 has been studied in two completed Phase 1 trials: NCT00712829, which evaluated safety, pharmacokinetics, and dosimetry in prostate cancer patients, and NCT00992745, a pilot study comparing 123I MIP 1072 to 111In capromab pendetide in metastatic prostate cancer. Both trials were conducted in the United States.
123-I-MIP-1072 is a small molecule imaging agent designed to target prostate cancer cells. It is intended to bind to specific molecular targets associated with prostate cancer, allowing visualization of tumors through imaging techniques. The exact molecular target has not been disclosed in available information.